Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
- PMID: 8120958
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
Abstract
Objective: To determine the efficacy of treatment using high-dose bolus interleukin 2 (IL-2) in patients with metastatic melanoma or renal cell cancer.
Design and setting: Consecutive series of all patients treated with high-dose IL-2 in the Surgery Branch of the National Cancer Institute from September 1985 through December 1992.
Patients: Two hundred eighty-three patients with metastatic melanoma or metastatic renal cell cancer who had failed standard treatment for their cancers.
Interventions: Patients received IL-2 at a dose of 720,000 IU/kg intravenously every 8 hours for a maximum of 15 doses per cycle. Two cycles constituted a treatment course, and patients with stable or responding disease received additional treatment courses. A total of 447 courses of treatment were administered.
Main outcome measures: Regression of measurable tumor, durability of response to treatment, and survival.
Results: Nine patients (7%) with metastatic melanoma achieved complete regression of all disease and 14 patients (10%) had partial regression. Ten patients (7%) with metastatic renal cell cancer experienced complete regression and 20 patients (13%) had partial regression. Of the 19 patients with complete regression, 15 have remained in complete remission from 7 to 91 months after treatment. Three treatment-related deaths (1.1%) occurred early in this series, but as experience with the administration of this IL-2 regimen increased, no treatment-related deaths occurred in 214 patients treated during the last 5 years of the study.
Conclusion: Biologic therapy with IL-2 can cause significant antitumor effects in patients with advanced metastatic melanoma or renal cell cancer. Because IL-2 does not have a direct effect on cancer cells but rather mediates its antitumor activity by altering host immune reactions, these data represent the best available evidence that immunologic therapy for cancer can be effective in selected patients.
Comment in
-
Treatment of metastatic melanoma and renal cell carcinoma with interleukin-2.JAMA. 1994 Nov 2;272(17):1327. JAMA. 1994. PMID: 7933390 No abstract available.
-
Immunotherapy for metastatic cancer. Establishing a 'proof of principle'.JAMA. 1994 Mar 23-30;271(12):945-6. JAMA. 1994. PMID: 8120965 No abstract available.
Similar articles
-
Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.J Clin Oncol. 2000 May;18(9):1954-9. doi: 10.1200/JCO.2000.18.9.1954. J Clin Oncol. 2000. PMID: 10784637
-
Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.Rev Med Univ Navarra. 1996 Jul-Sep;40(3):6-12. Rev Med Univ Navarra. 1996. PMID: 9499820 Clinical Trial.
-
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.Ann Surg. 1998 Sep;228(3):307-19. doi: 10.1097/00000658-199809000-00004. Ann Surg. 1998. PMID: 9742914 Free PMC article. Clinical Trial.
-
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.J Clin Oncol. 1999 Jul;17(7):2105-16. doi: 10.1200/JCO.1999.17.7.2105. J Clin Oncol. 1999. PMID: 10561265 Review.
-
[Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)].Actas Urol Esp. 1995 Jan;19(1):16-26. Actas Urol Esp. 1995. PMID: 7717154 Review. Spanish.
Cited by
-
PD-1 and PD-L1 antibodies for melanoma.Hum Vaccin Immunother. 2014;10(11):3111-6. doi: 10.4161/21645515.2014.983409. Hum Vaccin Immunother. 2014. PMID: 25625924 Free PMC article. Review.
-
The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma.Indian J Urol. 2021 Jan-Mar;37(1):13-19. doi: 10.4103/iju.IJU_293_20. Epub 2021 Jan 1. Indian J Urol. 2021. PMID: 33850351 Free PMC article. Review.
-
Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment.Nutr J. 2016 May 4;15(1):47. doi: 10.1186/s12937-016-0167-8. Nutr J. 2016. PMID: 27142426 Free PMC article. Review.
-
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).J Transl Med. 2012 Dec 10;10:246. doi: 10.1186/1479-5876-10-246. J Transl Med. 2012. PMID: 23228035 Free PMC article. Clinical Trial.
-
Evolving Immunotherapy Approaches for Renal Cell Carcinoma.Curr Oncol Rep. 2016 Sep;18(9):57. doi: 10.1007/s11912-016-0542-9. Curr Oncol Rep. 2016. PMID: 27475806 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical